Efficacy and Safety of Infliximab versus Methotrexate in Patients with Moderate-to-Severe Plaque Psoriasis: Results of an Open-Label, Active-controlled, Randomized Trial (RESTORE1)

Abstract

Background:  Infliximab is indicated for treatment of moderate-to-severe plaque psoriasis in adults whose disease cannot be controlled with other systemic therapies, including methotrexate (MTX). To date, no studies have directly compared the efficacy and safety of infliximab and MTX.


Objective:  To compare the efficacy and safety of infliximab versus MTX in adults with moderate-to-severe plaque psoriasis.


Patients and Methods:  868 MTX-naïve patients were randomized 3:1 to receive infliximab 5 mg/kg at weeks 0, 2, 6, 14 and 22 or MTX 15 mg/wk with a dose increase to 20 mg/wk at week 6 ...

Efficacy and Safety of Infliximab versus Methotrexate in Patients with Moderate-to-Severe Plaque Psoriasis: Results of an Open-Label, Active-controlled, Randomized Trial (RESTORE1) is a post from: Skincare

Efficacy and Safety of Infliximab versus Methotrexate in Patients with Moderate-to-Severe Plaque Psoriasis: Results of an Open-Label, Active-controlled, Randomized Trial (RESTORE1) via BuzzBlazer.com